Immunological reconstitution after autologous peripheral blood stem cell transplantation in patients with chronic lymphocytic leukemia.: Comparison with an historical non-Hodgkin's lymphoma group

被引：0

作者：

Laurenti, L ^{[1
]}

Piccirillo, N ^{[1
]}

Sorà, F ^{[1
]}

Piccioni, P ^{[1
]}

Tarnani, M ^{[1
]}

Leone, G ^{[1
]}

Sica, S ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Div Ematol, Rome, Italy

来源：

HAEMATOLOGICA | 2004年 / 89卷 / 01期

关键词：

immune recovery; hematologic reconstitution; chronic lymphocytic leukemia;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The kinetics of immune reconstitution after autologous peripheral blood stem cell transplantation (APBSCT) was examined in a group of 6 patients with chronic lymphocytic leukemia (CLL) and compared to that in an historical group of 12 patients with non-Hodgkin's lymphoma (NHL). Lymphocyte analysis included total lymphocyte count, CD3, CD4, CD8, CD4/8 ratio, CD19, and CD16/56 counts before, on day +15, +30, +60, +90, and +120 and 1 year after transplantation. Immunological recovery in the CLL group was similar to that in the NHL group.

引用

页码：120 / 122

页数：3

共 45 条

[41] Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development
Kubuschok, Boris
Trepel, Martin
EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (07) : 733 - 745
[42] Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody
Goede, Valentin
Klein, Christian
Stilgenbauer, Stephan
ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (04) : 185 - 192
[43] Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease
J Mattsson
M Uzunel
M Remberger
P Ljungman
E Kimby
O Ringdén
H Zetterquist
Leukemia, 2000, 14 : 247 - 254
[44] Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease
Mattsson, J
Uzunel, M
Remberger, M
Ljungman, P
Kimby, E
Ringdén, O
Zetterquist, H
LEUKEMIA, 2000, 14 (02) : 247 - 254
[45] Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
St-Pierre, Frederique
Doukas, Peter
Boyer, Jennifer
Nieves, Mariana
Ma, Shuo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S273 - S273

← 1 2 3 4 5 →